Humacyte Inc (HUMA) Q3 2025 Earnings Call Highlights: Strong Symvess Sales Growth Amidst ... [Yahoo! Finance]
Humacyte, Inc. (HUMA)
Company Research
Source: Yahoo! Finance
Research Collaboration Revenue: $0.1 million from a collaboration with a medical technology company. Cost of Goods Sold: $0.3 million for Q3 2025. Research and Development Expenses: $17.3 million for Q3 2025, down from $22.9 million in Q3 2024. Selling, General, and Administrative Expenses: $7.6 million for Q3 2025, up from $7.3 million in Q3 2024. Other Net Income: $6.9 million for Q3 2025, compared to a net expense of $9.0 million in Q3 2024. Net Loss: $17.5 million for Q3 2025, compared to $39.2 million in Q3 2024. Cash Equivalents and Restricted Cash: $19.8 million as of September 30, 2025. Additional Cash Proceeds: $56.5 million from the sale of common stock and warrants post-September 30, 2025. Net Cash Used in Operating Activities: $78.9 million for the first nine months of 2025, compared to $71.5 million for the same period in 2024. Warning! GuruFocus has detected 5 Warning Signs with HUMA. Is HUMA fairly valued? Test your thesis with our free DCF calculat
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Humacyte (HUMA) Q3 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $6.00 price target on the stock.MarketBeat
- Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.MarketBeat
HUMA
Earnings
- 11/12/25 - Beat
HUMA
Sec Filings
- 11/26/25 - Form 8-K
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- HUMA's page on the SEC website